HUTCHMED (NASDAQ:HCM) Lowered to Hold Rating by StockNews.com

HUTCHMED ( NASDAQ:HCM – Get Free Report ) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Monday. Separately, The Goldman Sachs Group increased their price objective on shares of HUTCHMED from $17.

00 to $19.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. Check Out Our Latest Report on HUTCHMED HUTCHMED Stock Performance Institutional Inflows and Outflows A number of large investors have recently added to or reduced their stakes in HCM.



M&G PLC grew its position in shares of HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after buying an additional 132,333 shares during the last quarter.

Renaissance Technologies LLC lifted its stake in shares of HUTCHMED by 74.8% in the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock worth $2,248,000 after acquiring an additional 56,200 shares during the period.

Jane Street Group LLC lifted its stake in shares of HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after acquiring an additional 49,366 shares during the period.

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in HUTCHMED by 99.0% in the third quarter.

Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock valued at $952,000 after acquiring an additional 24,245 shares during the last quarter. Finally, Bellevue Group AG increased its position in HUTCHMED by 2.

1% during the 1st quarter. Bellevue Group AG now owns 1,154,632 shares of the company’s stock valued at $19,398,000 after purchasing an additional 23,521 shares during the period. Institutional investors own 8.

82% of the company’s stock. About HUTCHMED ( Get Free Report ) HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.

Featured Articles Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter ..